©2022 Stanford Medicine
An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Not Recruiting
Trial ID: NCT00932893
Purpose
This is a Phase 3 trial comparing the safety and anti-tumor activity of PF-02341066 versus
pemetrexed or docetaxel in patients with advanced non-small cell lung cancer with specific
gene profile involving the ALK gene after failure of one previous chemotherapy regimen that
included one platinum drug.
Official Title
Phase 3, Randomized, Open-label Study Of The Efficacy And Safety Of Pf-02341066 Versus Standard Of Care Chemotherapy (Pemetrexed Or Docetaxel) In Patients With Advanced Non-small Cell Lung Cancer (Nsclc) Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (Alk) Gene Locus
Stanford Investigator(s)
A. Dimitrios Colevas, MD
Professor of Medicine (Oncology) and, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS) and of Radiation Oncology (Radiation Therapy)
Heather Wakelee
Professor of Medicine (Oncology)
George A. Fisher Jr.
Colleen Haas Chair in the School of Medicine
Eligibility
Inclusion Criteria:
- histologically or cytologically proven diagnosis of non-small cell lung cancer
- positive for the ALK fusion gene (test provided by a central laboratory)
- must have had disease progression after only one prior chemotherapy and that regimen
but must have included one platinum drug
- tumors must be measurable
Exclusion Criteria:
- prior treatment with PF-02341066
- current treatment in another clinical trial
Intervention(s):
drug: PF-02341066
drug: Pemetrexed
drug: Docetaxel
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Cancer Clinical Trials Office
650-498-7061